- Home
- LUNG vs DMAC Comparison
LUNG vs DMAC Comparison
Compare LUNG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- DMAC
- Stock Information
- Founded
- LUNG 1995
- DMAC 2000
- Country
- LUNG United States
- DMAC United States
- Employees
- LUNG N/A
- DMAC N/A
- Industry
- LUNG Industrial Specialties
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- DMAC Health Care
- Exchange
- LUNG Nasdaq
- DMAC Nasdaq
- Market Cap
- LUNG 299.3M
- DMAC 267.7M
- IPO Year
- LUNG 2020
- DMAC N/A
- Fundamental
- Price
- LUNG $7.76
- DMAC $5.07
- Analyst Decision
- LUNG Strong Buy
- DMAC Strong Buy
- Analyst Count
- LUNG 7
- DMAC 3
- Target Price
- LUNG $12.64
- DMAC $8.00
- AVG Volume (30 Days)
- LUNG 464.2K
- DMAC 74.9K
- Earning Date
- LUNG 04-30-2025
- DMAC 03-17-2025
- Dividend Yield
- LUNG N/A
- DMAC N/A
- EPS Growth
- LUNG N/A
- DMAC N/A
- EPS
- LUNG N/A
- DMAC N/A
- Revenue
- LUNG $83,789,000.00
- DMAC N/A
- Revenue This Year
- LUNG $17.96
- DMAC N/A
- Revenue Next Year
- LUNG $18.35
- DMAC N/A
- P/E Ratio
- LUNG N/A
- DMAC N/A
- Revenue Growth
- LUNG 22.01
- DMAC N/A
- 52 Week Low
- LUNG $5.46
- DMAC $2.14
- 52 Week High
- LUNG $10.01
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- LUNG 52.43
- DMAC 37.74
- Support Level
- LUNG $7.65
- DMAC $5.49
- Resistance Level
- LUNG $8.12
- DMAC $6.11
- Average True Range (ATR)
- LUNG 0.49
- DMAC 0.34
- MACD
- LUNG -0.06
- DMAC -0.09
- Stochastic Oscillator
- LUNG 45.14
- DMAC 8.97
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.